Trace Neuroscience Launches with $101M to Target ALS and Neurodegenerative Diseases
Slice of Healthcare Team
11/15/2024
Key Highlights
- $101M Series A funding led by Third Rock Ventures and others, supporting ALS and neurodegenerative therapies.
- UNC13A-focused therapy aims to improve nerve-muscle communication in ALS patients.
- Lead program: antisense oligonucleotide (ASO) to target sporadic ALS, affecting 90% of patients.
- Broad potential impact on ALS, frontotemporal dementia, and Alzheimer's with TDP-43 pathology.
Source: Business Wire
Notable Quotes
“ UNC13A restoration has the potential to deliver meaningful innovation that will improve their quality of life and overall health outcomes. ”
Jeffrey Tong, Ph.D., Partner at Third Rock Ventures
“ We envision a world where UNC13A restoration improves outcomes across a range of neurodegenerative diseases. ”
Eric Green, M.D., Ph.D., CEO at Trace Neuroscience
“ Our insights into UNC13A biology may be the key to slowing disease progression, preserving or restoring muscle function and extending survival for people living with ALS. ”
Aaron Gitler, Ph.D., Professor of Genetics at Stanford University
